新辅助化疗加免疫疗法治疗局部晚期食道癌
Jingyue Zhou1, Gan Zhang1, Minghua Xie1
1Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China Hefei 230031, Anhui, China.
使用卡姆雷利祖马布 (PD-1 抑制剂) 的新辅助化疗对局部发达的食道癌症表现出良好的疗效和安全性. 特别是PD-1阳性患者从改善的预后和无进展的生存期中受益.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 局部发达的食道癌症带来了重大的治疗挑战.
- 新辅助化疗是一种标准的治疗方式.
- 免疫疗法的作用,特别是PD-1抑制剂,是目前正在积极研究的领域.
研究的目的:
- 评估新辅助化疗与卡梅利祖马布 (一种编程死亡-1 (PD-1) 抑制剂) 结合的疗效和安全性,用于局部晚期食道癌患者.
- 评估PD-1表达对治疗结果的影响.
主要方法:
- 对87名患有局部晚期食道癌的患者进行了回顾性分析.
- 患者在2018年6月至2021年4月期间接受了新辅助化疗加上camrelizumab.
- 对术后临床结果和PD-1表达水平的评估.
主要成果:
- 较高的疾病控制率 (83.91%) 和客观反应率 (59.77%).
- 与PD-1-阴性瘤相比,PD-1-阳性瘤显示出明显更高的客观反应率和12个月无进展生存期.
- 良好的安全性概况,有10.34%的III级不良事件发生率,没有IV级或更高的事件.
结论:
- 新辅助化疗加上卡姆雷利祖马布在局部发达的食道癌症中是有效和安全的.
- 阳性PD-1状态与改善的预后和无进展的存活率有关.
- 这种组合疗法为这种患者群体提供了一个有前途的治疗策略.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:42Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
Published on: July 6, 2022
相关概念视频
Tumor Immunotherapy
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
